Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection

OBJECTIVE

To examine the effect of radical nephrectomy (RN) with adjacent organ and structure resection on survival, as invasion of adjacent organs in patients with renal cell carcinoma (RCC) is rare.

PATIENTS AND METHODS

After institutional review board approval, we reviewed our database and statistically analysed of patients with pathological stage T3 or T4 RCC who had RN and resection of a contiguous organ or structure.

RESULTS

We identified 38 patients of 2464 (1.5%) who had RN with adjacent organ or structure resection. The median (interquartile range) size of the mass was 11 (8–14) cm, and the follow‐up 13 (5–33) months. Most patients (68%) were pT4 stage and had conventional clear cell carcinoma (95%). Fourteen patients (37%) had positive surgical margins. The liver (10) was the most commonly resected adjacent organ or structure. Only one patient remains alive with no evidence of disease at 5 years, while three are currently alive with disease. Overall, 34 of 38 patients (90%) ultimately died from disease at a median (range) of 11.7 (5.4–29.2) months after surgical resection. The surgical margin status was the only statistically significant factor for recurrence and death (P = 0.006).

CONCLUSIONS

The prognosis for patients with advanced RCC and adjacent organ or structure involvement is extremely poor and similar to that of patients with metastatic disease. These patients should be thoroughly counselled about the impact of surgical management and considered for entry into neoadjuvant or adjuvant clinical trials with new targeted systemic agents.     

Imaging techniques for the patient with renal cell carcinoma

The imaging of renal cell carcinoma continues to evolve from radiographic tomography to state-of-the-art three-dimensional imagery using computed tomography (CT) or magnetic resonance imaging (MRI). This article reviews the current techniques of imaging the patient with renal cell carcinoma. Careful and accurate imaging of these patients allows for the appropriate diagnosis, treatment planning, and follow-up care. At each point in the care of these patients, imaging plays an important role. In particular, the diagnosis and staging of renal cell carcinoma can be accomplished with CT and MRI, with each modality having strengths and weaknesses that are contrasted. Intraoperative ultrasound is used during laparoscopic or conventional partial nephrectomies, whereas ultrasound, CT, and MRI can be used for guiding ablative technologies. Imaging also plays an important role in the follow-up care of these patients. The particular follow-up care is dependent on the stage and grade of the lesion and the treatment modality used. In summary, this article reviews the current imaging approaches for the diagnosis, staging, treatment, and follow-up care of patients with renal cell carcinoma.     

Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer,bladder cancer and renal cell carcinoma

Objectives: To identify an appropriate reference gene for the analysis of circulating micro‐ribonucleic acid in patients with urological malignancies. Methods: Serum from patients with prostate cancer (n = 24), bladder cancer (n = 24), renal cell carcinoma (n = 24) and control subjects (n = 48) was spiked with cel‐miR‐39, and then ribonucleic acid was isolated. Quantitative real‐time polymerase chain reaction was used to determine the levels of candidate reference genes (RNU1‐4, RNU6‐2, SNORD43, SNORD44, SNORD48, SNORA74A, miR‐let‐7a‐1, miR‐106a). Reference gene stability was determined using the NormFinder, geNorm and comparative delta‐Ct algorithm. The effect of normalization was tested with miR‐21 as the target gene, as this was previously suggested to be upregulated in cancer patients' serum. Results: Recovery of cel‐miR‐39 (mean 11.6%, range 1–56%) was similar in control subjects and cancer patients. SNORD44 and SNORD74A levels were around the detection limit of the assay and were thus omitted. All remaining candidates showed satisfying stability; SNORD43 was the most stable reference gene using all three algorithms. A combination of two genes (SNORD43, RNU1‐4) increases the stability somewhat. The level of miR‐21 was similar in cancer patients and healthy controls, irrespective of the normalization strategy. Conclusions: SNORD43 is a suitable reference gene for the analysis of circulating micro‐ribonucleic acid in patients with urological malignancies. Our study questions the suitability of miR‐21 as a biomarker for uro‐oncological patients.     

Impact of body mass index on survival of patients with surgically treated renal cell carcinoma

PURPOSE: Population studies link increased BMI with an increased risk of cancer and cancer mortality and in particular a greater risk of RCC. We evaluated the impact of BMI and other clinical/pathological characteristics on survival in patients with RCC treated with radical or partial nephrectomy. MATERIALS AND METHODS: Between 1995 and 2003 patients undergoing radical (760) or partial (399) nephrectomy for RCC were entered into a database. BMI data were available on 1,137 of 1,159 (98%). Demographic and clinical/pathological parameters were analyzed. World Health Organization BMI definitions (normal-less than 25 kg/m(2), overweight-25 to 29.9 kg/m(2), obese-30 kg/m(2) or more) were used. RESULTS: A total of 75% of patients had greater than normal BMI with 472 (41.5%) overweight and 387 (34.0%) obese. Median followup was 33 months with a median overall survival of 110 months and a 5-year overall survival probability of 0.79. BMI categories were similar in age, gender, smoking status, presenting symptoms, tumor size, stage, and type of surgery. Significant increases in blood loss and operative time (p <0.05) were seen with increasing BMI. Although BMI 30 kg/m(2) or greater was associated with a higher proportion of clear cell histology (p = 0.002), it did not translate into an increased pathological stage, or incidence of metastasis. Multivariate analysis revealed age older than 65 years, systemic symptoms, surgery type, and pathological stage impacted overall survival (p <0.05). CONCLUSIONS: Although an increased BMI was associated with a greater proportion of clear cell histology, comorbidity, and surgical morbidity, BMI did not adversely impact overall or progression-free survival.     

Combined small cell carcinoma and sarcomatoid squamous cell carcinoma in the renal pelvis

We report here a case of combined small cell carcinoma and sarcomatoid squamous cell carcinoma in the renal pelvis. A 61-year-old female presented with right flank discomfort, microhematuria and progressive renal dysfunction. Following diagnosis of right renal pelvic carcinoma, radical nephroureterectomy with lymph node dissection was performed through a midline incision. The tumor was pathologically diagnosed to be combined small cell carcinoma and sarcomatoid squamous cell carcinoma in the renal pelvis. The patient had no evidence of recurrence or metastasis, 16 months postoperatively. Small cell carcinoma or sarcomatoid squamous cell carcinoma of the renal pelvis is very rare. We believe this is the first such case to be reported in the world.     

A risk index for prostate cancer

BACKGROUND: The aim of the present study was to create a simple numerical index predicting the presence of prostate cancer in a group of high risk patients, for the purpose of selecting those most likely to need prostate biopsy. METHODS: 100 consecutive patients at high risk of having prostate cancer seen at Ramathibodi Hospital, Thailand between November 2000 and February 2002 were prospectively studied. All patients underwent transrectal prostate biopsies. The following predictor variables were obtained: age, digital rectal examination (DRE) findings, prostate specific antigen level, transrectal ultrasonography (TRUS) findings, and prostate volume determined by TRUS. The outcome was the presence of prostate cancer on histological examination of the biopsy specimens. A risk index for prostate cancer based on the linear predictor of a multiple logistic regression model was created. RESULTS: Almost all predictor variables were significantly related to the presence of prostate cancer. The final multiple logistic regression model with four categorized predictors (excluding DRE) was shown to have good discrimination, calibration, and cross-validity. For a cutoff risk index of 10, corresponding to a 10% probability of having prostate cancer, the sensitivity for detecting prostate cancer was 96.2%, with a specificity of 73.0%. Based on this cutoff, 55% of patients in this series might not require prostate biopsy. CONCLUSION: A risk index for prostate cancer was developed. If this index can be externally validated, the potential savings from avoiding unnecessary prostate biopsies, on the basis of selection using the index, could be significant.     

Impact of body mass index on perioperative outcomes of laparoscopic radical nephrectomy in Japanese patients with clinically localized renal cell carcinoma

Objective: The aim of this study was to review the association between body mass index (BMI) and perioperative outcomes of laparoscopic radical nephrectomy (LRN) in Japanese patients with renal cell carcinoma (RCC). Methods: This study included 108 consecutive Japanese patients undergoing LRN for RCC between April 2001 and March 2009. These patients were divided into the following two groups according to BMI: the non‐obese group (n= 58, BMI 25 kg/m² or less) and the obese group (n= 50, BMI greater than 25 kg/m²). Perioperative outcomes between these two groups were retrospectively compared. Results: There were no significant differences in clinicopathological parameters other than BMI between the non‐obese and obese groups. There were no significant differences in operative time, estimated blood loss during LRN, and the incidences of open conversion and postoperative complications between these two groups. In addition, there were no significant differences in parameters related to postoperative recovery, including time to walk, time to oral intake and time until permission for discharge, between these two groups. However, significant trends toward a prolonged operative time (P= 0.0050) and increased blood loss (P= 0.012) during LRN in relation to BMI were documented by linear regression analyses. Conclusions: Although the degree of obesity in patients included in this study was comparatively slight, these findings suggest that LRN can be safely performed for patients with RCC irrespective of BMI. However, the difficulty of LRN may increase with BMI considering the trends toward longer operative time as well as greater blood loss.     

结石肾并肾癌的诊断和治疗

目的 探讨结石肾合并肾癌的诊断与治疗策略.方法 回顾分析9例结石肾合并肾癌患者的病例资料及诊治经过.结果 9例患者中2例术前检查已发现结石肾合并肾占位病变行根治性肾切除;另7例中4例因结石手术术中发现可疑病灶行快速冰冻切片病检证实为肾细胞癌而行根治性肾切除,3例因结石肾积水合并感染形成脓肾行患肾切除,术后病理证实为肾癌...     

Squamous cell carcinoma of the prostate

Squamous cell carcinoma of the prostate is rare, accounting for 0.5-1% of all prostatic cancers. It is highly aggressive and responds poorly to any mode of therapy. We present a case of squamous cell carcinoma of the prostate that developed in a patient with prostatic adenocarcinoma following radiation therapy.     

Adenosquamous carcinoma of the prostate

Adenosquamous carcinoma of the prostate is an unusual histological variant of prostate cancer. The histogenesis of this tumor remains uncertain. The stimulus for the development of the squamous metaplastic cells had been thought to be related to hormone and/or radiation therapy. This report presents a case of adenosquamous carcinoma of the prostate with abscence of previous hormone or radiation therapy. The case showed negative prostate-specific antigen and high molecular weight cytokeratin staining of the adenocarcinoma component, and negative prostate-specific antigen and positive high molecular weight cytokeratin staining of the squamous cell carcinoma component. The adenocarcinoma component stained intraluminally with periodic acid schiff. The staining features and the distinct localizations of the components with intermingling, but no transition, are against the collision-type tumor theory and support the theory that the adenocarcinoma and squamous components arise de novo from pluripotent stem cells. The patient had a rapid downhill clinical course and died 3 weeks after the diagnosis was made.     

Small cell carcinoma of the prostate with hypercalcemia

We present a case of small cell prostate carcinoma with hypercalcemia in a 75-year-old man. He was diagnosed as having stage T3bN1M0 adenocarcinoma of the prostate. His serum prostate-specific antigen level was reduced to below the normal range after a combination treatment of a luteinizing hormone-releasing hormone agonist and flutamide for prostate carcinoma. He subsequently experienced increasing fatigue, poor appetite, short time loss of consciousness and pain in his lower abdomen. His serum calcium level and carcinoembryonic antigen were increased. He died 5 months from the start of treatment. The autopsy revealed small cell carcinoma of the prostate and multiple metastasis of the lung, liver, pancreas, lymph nodes and spine.     

The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy

OBJECTIVE

To assess whether under‐ or overweight at the time of surgery has any effect on the survival of the patients with renal cell carcinoma (RCC), as obesity increases the risk of developing RCC.

PATIENTS AND METHODS

We prospectively evaluated 780 patients who had nephrectomy for RCC between 1990 and 2005. We used uni‐ and multivariate Cox proportional hazards models to assess the effect of body mass index (BMI), tumour stage, Fuhrman grade, age, sex, histological type and performance status on cancer‐specific survival (CSS). Patients were grouped according to BMI (in kg/m²), as underweight (<18.5), normal (18.5–<25), overweight (25–<30) and obese (≥30).

RESULTS

The median (range) follow‐up was 5.3 (0.5–15.4) years, the patients being followed until June 2006; 254 patients died during the follow‐up. Multivariate analyses of all patients showed that tumour stage, Fuhrman grade, Karnofsky performance status, age, sex and BMI were independent prognostic factors for CSS. While underweight patients had a significantly worse prognosis than those of normal weight, overweight or obese patients had a similar outcome to that of patients of normal weight. In a subgroup analyses including patients with localized RCC only, there was a strong tendency to less aggressive disease in the overweight group (P = 0.081).

CONCLUSIONS

Being underweight is an unfavourable and new risk factor for CSS in patients with RCC treated by nephrectomy. Although not significant, there seems to be a limited favourable prognostic effect of overweight on CSS in patients with localized RCC.     

Surgery for localized prostate cancer after renal transplantation

OBJECTIVE: To investigate the feasibility of perineal radical prostatectomy (RP) in renal transplant recipients with localized prostate cancer. PATIENTS AND METHODS: The study comprised seven consecutive renal transplant patients who had a perineal RP between May 1991 and February 2004. All available clinicopathological data were reviewed. Results All seven patients successfully tolerated RP with no major complications. The mean (sd, range) age at surgery was 62.3 (2.5, 55-74) years and the mean interval from renal transplant to RP 86.5 (25.25, 24-192) months. There was no evidence of increased blood loss, operative duration, transfusion requirement, hospital stay or deterioration of graft function. The presence of an allograft did not alter the surgical approach or management of the patients after RP. The mean follow-up was 22 (2-130) months and all seven patients were followed. One patient had evidence of biochemical recurrence with no radiographic evidence of metastatic disease. Serum prostate-specific antigen was undetectable in the remaining patients. CONCLUSION: A perineal RP in renal transplant recipients for treating localized prostate cancer offers many advantages over other treatments.     

肾肿瘤剜除术治疗肾细胞癌、肾血管平滑肌脂肪瘤

目的探讨肾肿瘤剜除术治疗肾细胞癌及肾血管平滑肌脂肪瘤的疗效。方法回顾分析15例在我院进行肾肿瘤剜除术的肾细胞癌及肾血管平滑肌脂肪瘤患者的临床及病理资料。结果全部肾肿瘤均成功剜除,平均热缺血时间为15min,术中肿瘤剜除面平均出血25ml,术后无继发出血,无急性肾小管坏死、慢性肾功能不全及尿瘘等并发症发生。术后平均随访时间为2．5年,均未见肿瘤复发或转移。依据2003AJCC肾癌分期方法,所有肾癌患者均为Tla期,组织学形态为透明细胞癌。病理分级按Fuhrman标准为G1。结论肾肿瘤剜除术对有假性包膜的Tla肾细胞癌和肾血管平滑肌脂肪瘤是有效和安全的,术后并发症少,可以最大程度地保留肾脏功能。     

偶发肾癌和症状肾癌临床诊疗特点比较的Meta分析

目的 比较偶发肾癌和症状肾癌的临床诊疗特点,阐述早期检出肾癌的重要意义.方法 检索Medline、PubMed、Cochrane Library、Web of Science、万方数据库、CNKI中文期刊数据库2000年1月1日至2016年12月31日国内外公开发表的所有关于偶发肾癌和症状肾癌临床研究的文献,按照纳入和排除标准对文献进行筛选,对纳入研究的文献进行数据提取和质量评价,采用Review Manager 5.3软件进行Meta分析.结果 共纳入23篇文献,总计肾癌患者10 065例,其中偶发肾癌患者4 251例,症状肾癌患者5 814例.两组患者在肿瘤直径上平均差(MD)为-1.58(95% CI:-2.05~-1.11),在肿瘤病理分级(G1和G2)、保留肾单位手术例数、临床分期(T1和T2)、淋巴结转移、远处器官转移上比值比(OR)分别为3.01(95% CI:2.62~3.45)、3.47(95% CI:2.72~4.44)、3.95(95% CI:3.24~4.81)、0.20(95% CI:0.11~0.35)和0.24(95% CI:0.17~0.35),差异均有明显统计学意义(P<0.000 1);在手术年龄上MD为0.23(95% CI:-1.64~2.09),差异无统计学意义(P=0.81).结论 与症状肾癌相比,偶发肾癌具有肿瘤体积小、肿瘤病理分级低、临床分期早、淋巴结转移及远处器官转移少等特点,因此早期发现肾癌对提高患者生活质量及生存率十分重要.